Clinical Research Directory

Inclusion criteria : * Age 18-75 years old * unilateral histologically confirmed invasive breast carcinoma of pT1-3 * breast conservation surgery or mastectomy * Breast reconstruction is allowed * histologically confirmed positive axillary lymph nodes (positive sentinel lymph nodes without axillary dissection is allowed) * Life expectancy of \>5 years * A minimum negative surgical margin width of \>2mm * Karnofsky Performance Status ≥80 * Estrogen-receptor, Progesterone-receptor, human epidermal growth factor receptor-2 (HER-2) and Ki67 index can be performed on the primary breast tumor or axillary nodes. * Written informed consent Exclusion criteria: * Supraclavicular lymph nodes, positive ipsilateral internal mammary lymph nodes or residual axillary nodes that may be eligible for a boost dose. * Pregnant or lactating * Severe non-neoplastic medical comorbidities * Diagnosis of non-breast malignancy within 5 years preceding enrollment (except for basal cell carcinoma of the skin or carcinoma in situ of the cervix). * Simultaneous contralateral breast cancer * Previous RT to thoracic and/or axillary, cervical region * Active collagen vascular disease * Evidence of distant metastatic disease and/or T4 disease Notes for exlusion criteria: 1. Patients with severe non-neoplastic medical comorbidities (e.g.,severe ischemic heart disease, severe arrhythmia or severe chronic obstructive pulmonary disease ) that would preclude radiation treatment will be excluded. 2. Simultaneous contralateral breast cancer includes histologically confirmed DCIS only.